The results of treatment of 15 patients with GIST tumors from 2007 to 2010. We describe the clinical manifestations depending on the location and development of complications. Estimated the complexity and accuracy of preoperative diagnosis using different instrumental technigues in accordance with the recommendations of an international agreement in 2005. Accurate diagnosis can be established only by using immunohistochemical study,which is true in all cases the presence of GIST tumors. As an additional method of imaging for suspected tumor site in the small intestine is used angiography of visceral abdominal arteries.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Transanal Minimally Invasive Surgery for a Gastrointestinal Stromal Tumor of the Lower Rectum: A Case Report.
Asian J Endosc Surg
January 2025
Department of Gastroenterological Surgery, Sakai City Medical Center, Osaka, Japan.
Rectal gastrointestinal stromal tumors (GISTs) are prevalent in the lower rectum, and the existing literature suggests that transanal interventions are advantageous for anorectal preservation. Herein, we present a case of rectal GIST resection using transanal minimally invasive surgery. A 75-year-old woman reported vaginal discomfort and was subsequently diagnosed with GIST via transanal tumor biopsy.
View Article and Find Full Text PDF18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors.
JAMA Netw Open
January 2025
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
Importance: The D842V platelet-derived growth factor receptor α (PDGFRA) mutation identifies a molecular subgroup of gastrointestinal stromal tumors (GISTs), primarily resistant to standard tyrosine kinase inhibitors and with an overall more indolent behavior. Although functional imaging with 18F-fluorodeoxyglucose-labeled positron emission tomography ([18F]FDG-PET) plays a proven role in GISTs, especially in early assessment of tumor response, less is known about [18F]FDG uptake according to the GIST molecular subtypes.
Objective: To evaluate the degree of [18F]FDG uptake in PDGFRA-mutant GISTs and better define the role of functional imaging in this rare and peculiar subset of GISTs.
Patient-derived xenograft models of gastrointestinal stromal tumors: a ready-to-use platform for translational research.
Dis Model Mech
January 2025
Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven Cancer Institute, Leuven, Belgium.
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal malignancy of the gastrointestinal tract. Most GIST harbor mutations in oncogenes, such as KIT, and are treated with tyrosine kinase inhibitors (TKI), such as imatinib. Most tumors develop secondary mutations inducing drug resistance against the available TKI, which requires novel therapies.
View Article and Find Full Text PDFHuaier inhibits the proliferation and migration of gastrointestinal stromal tumors by regulating the JAK2 / STAT3 signaling pathway.
J Ethnopharmacol
January 2025
Division of Gastric Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Drum Tower Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China; Division of Gastric Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Electronic address:
Ethnopharmacological Relevance: Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the digestive tract, often accompanied by a high risk of recurrence and drug resistance. Huaier (Trametes robiniophila Murr), a traditional Chinese medicinal fungus, has demonstrated potent anticancer properties and is widely used as an adjuvant treatment for liver, breast, gastric, colon, and non-small cell lung cancers. However, its effects and molecular mechanisms in GIST remain unclear.
View Article and Find Full Text PDFDesign, Synthesis, and SAR of Covalent KIT and PDGFRA Inhibitors─Exploring Their Potential in Targeting GIST.
J Med Chem
January 2025
Department of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Integrierte Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, Dortmund 44227, Germany.
Gastrointestinal stromal tumors (GIST), driven by KIT and PDGFRA mutations, are the most common mesenchymal tumors of the gastrointestinal tract. Although tyrosine kinase inhibitors (TKIs) have advanced treatment, resistance mutations and off-target toxicity limit their efficacy. This study develops covalent TKIs targeting drug-resistant GIST through structure-based design, synthesis, and biological evaluation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!